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Abstract Trefoil factor family (TFF) is a group of peptides
that play critical roles in maintaining gastric mucosal integrity.
In real-time quantitative reverse transcription-polymerase chain
reaction (RT-PCR) and reporter gene assays, we show that
indomethacin and aspirin upregulate TFF2 expression in
MKN45 gastric cells. These drugs also activated peroxisome
proliferator-activated receptor Q (PPARQ) at concentration
ranges that increase TFF2 expression, and upregulated TFF2
expression was suppressed by GW9662, a speci¢c inhibitor of
PPARQ. These results suggest that indomethacin and aspirin
upregulate gastric expression of TFF2 through activation of
PPARQ. This mechanism may be important in reducing the ex-
tent of gastric mucosal injury caused by the administration of
non-steroidal anti-in£ammatory drugs (NSAIDs).
3 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
A number of factors are involved in the defense of gastric
mucosa against acid and other endogenous as well as exoge-
nous noxious agents [1]. Among these gastroprotective fac-
tors, much attention has been focused on prostaglandins
(PGs) and their ‘cytoprotective’ actions [2^4]. Since non-ster-
oidal anti-in£ammatory drugs (NSAIDs), for example aspirin
and indomethacin, are inhibitors of cyclooxygenase (COX), a
key enzyme for the production of bioactive PGs, administra-
tion of NSAIDs is often associated with the induction of
gastric mucosal lesions such as erosions and ulcers [5,6]. How-
ever, NSAIDs are not always bad for the gastrointestinal tract
and recent evidence also shows anti-cancer e¡ects of NSAIDs
especially in the colon, suggesting that NSAIDs a¡ect gastro-
intestinal mucosa in many ways [7,8]. It is also interesting that
some of the pharmacological actions of NSAIDs appear to be
mediated by COX-independent pathways [9].
Trefoil factor family (TFF) is considered another important
gastroprotective factor [10^12]. TFF is a group of protease-
resistant polypeptides characterized by a conserved three-loop
motif, designated the TFF domain [10,12,13]. Among three
known TFF subtypes, TFF1 (pS2) and TFF2 (spasmolytic
polypeptide; SP) are expressed in gastric epithelial cells, while
TFF3 (intestinal trefoil factor; ITF) expression is found in the
goblet cells of the lower intestine [10,11,13]. Although the
mode of TFF action is not fully understood, TFF peptides
stabilize surface mucus gels by interacting with mucin core
proteins and facilitate restitution by promoting cell migration
at the site of mucosal injury [10^13]. Konturek et al. recently
reported in a rat model that gastric TFF2 expression is upreg-
ulated during repeated administration of aspirin [14]. Azar-
schab et al. also showed that aspirin upregulates TFF2 ex-
pression in human gastric cell lines [15]. These ¢ndings suggest
a possible interaction or cooperation between the PG-COX
pathway and TFF peptides in terms of gastric mucosal pro-
tection. Since further investigation of this issue may give bet-
ter understanding of the molecular mechanisms of gastric mu-
cosal protection, we examined the e¡ect of indomethacin and
aspirin on TFF expression in gastric epithelial cells. We report
here that indomethacin and aspirin upregulate gastric expres-
sion of TFF2 through activation of peroxisome proliferator-
activated receptor Q (PPARQ).
2. Materials and methods
2.1. Reagents and cell culture
Indomethacin and aspirin were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Prostaglandin E2 (PGE2), arachidonic acid (AA)
and GW9662 were purchased from Cayman Chemical (Ann Arbor,
MI, USA). To make stock solutions, indomethacin, aspirin, and
GW9662 were dissolved in dimethylsulfoxide (DMSO) (Sigma-Al-
drich). PGE2 and AA were dissolved in ethanol. In each experiment,
¢nal concentrations of the solvent were less than 0.1% and the solvent
itself did not a¡ect the result of the experiment. MKN45 and AGS,
cell lines derived from human gastric carcinoma, were obtained from
Human Health Resources Bank (Osaka, Japan) and were grown in
Ham’s F-12 culture medium (Invitrogen; Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum (Invitrogen).
2.2. Real-time quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Cells grown in 12-well plates were treated with the indicated agents
and total RNA was extracted from the cells with Trizol reagent (In-
vitrogen). First strand cDNA was made with You-Prime ¢rst strand
beads (Amersham Biosciences; Piscataway, NY, USA) using oligo
(dT) primers (Invitrogen). PCR primers used are summarized in Table
1. Real-time quantitative RT-PCR was performed in an ABI Prism
7700 sequence detection system (Applied Biosystems; Foster City,
CA, USA) using SYBR green reagents (Applied Biosystems) as de-
scribed previously [16]. After an initial 10 min at 95‡C, the reaction
was run for 35 PCR cycles of 15 s at 95‡C and 1 min at 56‡C. To
prepare standard samples, conventional RT-PCR was performed us-
ing the primers mentioned above and PCR products were puri¢ed
with Qiaquick PCR puri¢cation kit (Qiagen; Hilden, Germany). Pu-
ri¢ed PCR products were diluted and used as standard samples
(6U102 to 6U107 copies) for generating a standard curve for each
experiment.
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2.3. Reporter vectors and transient transfection assay
To make a TFF2 reporter gene construct, the 5P-£anking region of
the human TFF2 gene (GenBank accession number AB038162) was
PCR-ampli¢ed (3912 to +24) and cloned into the SmaI site of the
pGL3 basic luciferase reporter vector (Promega; Madison, WI, USA)
(TFF2-Luc). A reporter vector for monitoring PPAR activity was
made by inserting three times peroxisome proliferator responsive ele-
ment (PPRE) sequence [17] into the SmaI site of the pGL3 basic
luciferase vector (PPRE-Luc). Nucleotide identity and direction of
the inserts were veri¢ed by sequencing of both strands. TFF2-Luc
plasmid (0.6 Wg/well) or PPRE-Luc plasmid (0.6 Wg/well) was trans-
fected into MKN45 cells grown in a subcon£uent state in 24-well
plates using lipofectamine 2000 reagent (Invitrogen). pSV-L galacto-
sidase control vector (Promega) (0.1 Wg/well) was also transfected for
standardization. 4 h after transfection, the medium was replaced and
test agents were added. 24 h after the addition of the test agents, cells
were harvested by lysis bu¡er, and reporter gene assay was performed
in a microplate luminometer LB96V (Berthold Technologies; Bad
Wildbad, Germany). Luciferase assay system (Promega) and L-gal
reporter gene assay kit (Roche Diagnostics; Mannheim, Germany)
were used to measure ¢re£y luciferase activity and galactosidase ac-
tivity, respectively.
2.4. Statistics
Data are presented as the meanUS.D. Statistical di¡erences be-
tween two groups were analyzed by unpaired t-test. Analysis of var-
iance (ANOVA) was performed when more than two groups were
compared, and when signi¢cant (P6 0.05), Sche¡es multiple compar-
ison test was applied to test for the di¡erences between individual
groups. A P value 6 0.05 was considered to be signi¢cant.
3. Results
3.1. E¡ect of indomethacin on the expression of endogenous
TFF mRNA in MKN45 cells
Although MKN45 cells mainly expressed TFF1 and TFF2,
TFF3 mRNA was also detected by real-time quantitative RT-
PCR experiments as described in the previous paper [18]. To
examine the e¡ect of indomethacin on endogenous TFF
mRNA expression, MKN45 cells were treated with di¡erent
concentrations of indomethacin (0^250 WM) for 24 h and the
expression of each TFF subtype was analyzed by real-time
quantitative RT-PCR. As shown in Fig. 1, indomethacin
(30^250 WM) signi¢cantly upregulated TFF2 mRNA expres-
sion in a dose-dependent manner (Fig. 1B). High concentra-
tions of indomethacin also slightly upregulated TFF1 mRNA
expression (Fig. 1A). However, TFF3 mRNA expression was
not signi¢cantly a¡ected (Fig. 1C). In the following experi-
ments, we focused on the e¡ect of indomethacin on TFF2
expression. Fig. 1D shows a time-course experiment showing
the e¡ect of indomethacin (125 WM) on the expression of
TFF2 mRNA. Statistically signi¢cant upregulation was ob-
served after a 6-h treatment with indomethacin.
3.2. E¡ect of indomethacin on the transcription of the TFF2
reporter gene
Transient transfection assay was performed to con¢rm the
e¡ect of indomethacin on TFF2 transcription. After TFF2-
Luc was transfected to MKN45, cells were treated with indo-
methacin (0^250 WM) for 24 h. As shown in Fig. 2A, TFF2
transcription was upregulated by treatment with indomethacin
in a dose-dependent manner. Similar to the PCR experiment
described above, signi¢cant upregulation was observed at 30^
250 WM of indomethacin. Since indomethacin is a potent in-
Table 1
Primers used for real-time quantitative RT-PCR
TFF1 (GenBank acc. no. NM_003225) (product length 188 bp)
Sense 5P-CAATGGCCACCATGGAGAAC-3P
Antisense 5P-AACGGTGTCGTCGAAACAGC-3P
TFF2 (NM_005423) (product length 161 bp)
Sense 5P-CCAAAGCAAGAGTCGGATCAG-3P
Antisense 5P-CAGTCTTCCACAGACTTCGGG-3P
TFF3 (NM_003226) (product length 158 bp)
Sense 5P-TGTCTGCAAACCAGTGTGCC-3P
Antisense 5P-GCATTCTGTCTTCCTAGTCAGGG-3P
L-actin (NM_001101) (product length 204 bp)
Sense 5P-TTCCTGGGCATGGAGTCCT-3P
Antisense 5P-AGGAGGAGCAATGATCTTGATC-3P
Fig. 1. A^C: Quantitative RT-PCR experiments showing the e¡ects
of indomethacin (0^250 WM, 24-h incubation) on the expression of
endogenous TFF1 (A), TFF2 (B), and TFF3 (C) mRNA in
MKN45 gastric cells (n=4). *P6 0.01 vs. control. D: A representa-
tive time-course experiment showing the e¡ect of indomethacin (125
WM) on the expression of endogenous TFF2 mRNA in MKN45
cells (n=4). *P6 0.01 vs. control.
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hibitor of COX, we examined the e¡ect of externally applied
PGE2 on the indomethacin-induced upregulation of TFF2
transcription. MKN45 cells were pre-incubated with PGE2
(0.1^10 WM) for 2 h prior to the addition of indomethacin
(125 WM), and indomethacin was treated in the presence of
PGE2 for 24 h. As shown in Fig. 2B, PGE2 itself had a slight
stimulatory e¡ect on TFF2 transcription at 10 WM. Although
indomethacin-induced upregulation of TFF2 transcription
was partially suppressed by PGE2, most of the indomethacin
e¡ect remained, suggesting that PG depletion by indometha-
cin is not a main cause of TFF2 upregulation. We also tested
the e¡ect of AA, because there is a possibility that AA accu-
mulates when COX activity is suppressed by indomethacin.
However, externally applied AA (30 WM, 24-h incubation)
had no signi¢cant e¡ect on TFF2 transcription (Fig. 2C).
3.3. Indomethacin-induced PPARQ activation in MKN45 cells
and the e¡ect of GW9662 on indomethacin-induced
upregulation of TFF2 transcription
Indomethacin has been reported to act as a ligand for
PPARQ [19]. Since we have previously reported the expression
Fig. 2. A: E¡ect of indomethacin (0^250 WM, 24-h incubation) on
the transcription of TFF2 reporter gene (n=4). *P6 0.01 vs. con-
trol. B: E¡ect of externally applied PGE2 (0.1^10 WM) on indo-
methacin (Ind) (125 WM, 24-h incubation)-induced upregulation of
TFF2 reporter gene transcription (n=4). C: E¡ect of externally ap-
plied AA (30 WM, 24-h treatment) on the transcription of the TFF2
reporter gene (n=4).
Fig. 3. A: E¡ect of indomethacin (0^250 WM, 24-h incubation) on
the transcription of PPRE-driven reporter gene (n=4). *P6 0.01 vs.
control. B: E¡ect of GW9662 (GW) (30 WM) on indomethacin
(Ind) (125 WM, 24-h incubation)-induced upregulation of the tran-
scription of PPRE-driven reporter gene (n=4). C: E¡ect of
GW9662 (GW) (0.1^30 WM) on indomethacin (Ind) (125 WM, 24-h
incubation)-induced upregulation of the transcription of TFF2 re-
porter gene (n=4).
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of PPARQ in MKN45 cells [20], we tested whether indometh-
acin really activates PPARQ in this cell type. As shown in
Fig. 3A, indomethacin (30^250 WM) stimulated the transcrip-
tion of the PPRE-Luc reporter gene in a dose-dependent man-
ner and it was suppressed by GW9662 (30 WM), a speci¢c
inhibitor of PPARQ [21] (Fig. 3B), con¢rming the activation
of PPARQ by indomethacin in MKN45 cells. Thus, we exam-
ined the possible involvement of PPARQ in the indomethacin-
induced upregulation of TFF2 transcription. As shown in Fig.
3C, indomethacin (125 WM)-induced upregulation of TFF2
transcription was suppressed by GW9662 in a dose-dependent
manner, suggesting that indomethacin modulates TFF2 tran-
scription through PPARQ.
3.4. E¡ects of aspirin on PPARQ activity and TFF2
transcription in MKN45 cells
Although aspirin and salicylate are not regarded as ligands
for PPARQ [19], Azarschab et al. reported the upregulation of
TFF2 expression by aspirin at mM concentration ranges [15].
Thus, we next examined whether high concentrations of aspir-
in a¡ect PPARQ activity in MKN45 cells. As shown in Fig.
4A, aspirin at 5 mM caused about a 2.7-fold increase in
PPAR-Luc transcription and it was sensitive to GW9662 (30
WM), suggesting that PPARQ is activated in response to aspir-
in treatment. Fig. 4B shows the e¡ect of aspirin (5 mM) and
GW9662 (30 WM) on TFF2 transcription. We found that
TFF2 transcription was upregulated by aspirin and this up-
regulation was suppressed by GW9662. These results suggest
that, similar to indomethacin, aspirin a¡ects TFF2 expression
through PPARQ.
3.5. E¡ect of indomethacin and GW9662 on the expression of
endogenous TFF2 mRNA in MKN45 and AGS cells
Finally, we returned to RT-PCR experiments to determine
whether endogenous TFF2 mRNA expression is modulated
by indomethacin through a similar mechanism. Fig. 4A shows
the e¡ect of GW9662 on indomethacin-induced upregulation
of TFF2 mRNA expression in MKN45 cells. Similar to the
reporter gene experiments, GW9662 suppressed the indome-
thacin-induced upregulation of TFF2 mRNA expression in a
dose-dependent manner. We also tested another gastric cell
line, AGS, and found that GW9662 suppressed indometha-
cin-induced upregulation of TFF2 mRNA expression (Fig.
5B). Thus, the involvement of PPARQ in the action of indo-
methacin is not unique to MKN45.
4. Discussion
Genes encoding human TFF are clustered on chromosome
Fig. 4. A: E¡ects of aspirin (Asp) (5 mM, 24-h incubation) and
GW9662 (GW) (30 WM) on the transcription of PPRE-driven re-
porter gene (n=4). B: E¡ects of aspirin (Asp) (5 mM, 24-h incuba-
tion) and GW9662 (GW) (30 WM) on the transcription of TFF2 re-
porter gene (n=4).
Fig. 5. Quantitative RT-PCR experiments showing the e¡ects of in-
domethacin (Ind) (125 WM, 24-h incubation) and GW9662 (GW)
(10^30 WM) on the expression of endogenous TFF2 mRNA in
MKN45 cells (A) (n=4) and AGS cells (B) (n=4).
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21q22.3 [22] and a number of studies have reported the reg-
ulatory mechanisms of TFF gene expression [12,13]. Gott et
al. showed the presence of a TATA box and other potential
binding sites for Myc, PEA3, and Ets-like factor in the 5P-
£anking region of the TFF2 gene [22]. GATA-6 binding sites
are also considered to play a basic role in the stomach-speci¢c
expression of TFF2 [23]. Azarschab et al. recently examined
the e¡ect of aspirin on the expression of TFF in gastric cancer
cell lines, MKN45 and Kato3, and found that aspirin upreg-
ulates TFF2 expression. Since they observed that staurospo-
rine, an inhibitor of protein kinases including protein kinase
C, abolished this e¡ect of aspirin, they speculated that protein
kinase C is involved in the aspirin-induced upregulation of
TFF2 expression.
In the present study, we analyzed the mechanism of the
indomethacin-induced TFF2 expression in MKN45 cells.
Since externally applied PGE2 had little e¡ect on indometha-
cin-induced TFF2 expression, the depletion of PG by indome-
thacin was not likely to be a main trigger of TFF2 upregula-
tion. Although it is generally accepted that most of the
pharmacological actions of NSAIDs arise from inhibition of
COX and suppression of PG synthesis, evidence also suggests
the presence of possible targets of NSAIDs other than COX
[9]. Aspirin, for example, is known to inhibit the activity of
certain transcription factors, such as nuclear factor-UB (NF-
UB) and activator protein-1 (AP-1) [9], and aspirin also a¡ects
the activity of cellular kinases, such as mitogen-activated pro-
tein (MAP) kinases and cyclin-dependent kinases [9]. It has
been reported that indomethacin induces the expression of a
member of the TGF superfamily, designated NAG-1
(NSAIDs-activated gene-1) [24] and also induces the expres-
sion of a member of the nuclear receptor family, nerve growth
factor-inducible B (NGFI-B) [25]. More importantly, Leh-
mann et al. showed that indomethacin and some other
NSAIDs can act as ligands for PPARQ [19]. PPAR is a mem-
ber of the nuclear receptor superfamily and consists of three
subtypes, PPARK, PPARN, and PPARQ [26]. Among these
subtypes, PPARQ is expressed at a high level in adipose tissue
and is critically involved in the adipocyte di¡erentiation and
fatty acid metabolism [26].
Gastrointestinal epithelial cells also express PPARQ at a
signi¢cant level and a number of studies have suggested the
involvement of PPARQ in the regulation of cell proliferation,
di¡erentiation, and cell death of gastrointestinal epithelial
cells [26]. We have previously reported the expression and
functions of PPARQ in colon cancer cell lines and gastric
cancer cell lines, including MKN45 [16,20]. Recently, we
have observed the induction of TFF2 expression in MKN45
cells by 15-deoxy-v12;14-prostaglandin J2 and troglitazone,
which are established ligands for PPARQ [26]. In the present
study, we showed that indomethacin activates PPARQ in
MKN45 cells, and we found that indomethacin-induced
TFF2 expression is sensitive to GW9662, a speci¢c inhibitor
of PPARQ. Thus, it is very likely that indomethacin upregu-
lates TFF2 expression through PPARQ. Although aspirin has
not been considered a ligand for PPARQ [19,9], we also found
in the present study that aspirin activates PPARQ at high
concentrations, and that GW9662 suppresses aspirin-induced
TFF2 expression. Therefore, although possibility of the in-
volvement of other signaling pathways is not completely ex-
cluded, we hypothesize that PPARQ mainly mediates the ac-
tion of aspirin on TFF2 expression. Azarschab et al. [15]
mapped an aspirin responding element to 3546 to 3758 bp
upstream of the TATA box of the human TFF2 gene. Since
apparent PPRE is not present in the 5P-£anking region of the
human TFF2 gene, the e¡ect of PPARQ may be indirect. We
are currently investigating the PPARQ action on the TFF2
gene transcription in more detail.
Babyatsky et al. [27] and McKenzie et al. [28] showed a
gastroprotective role of oral or topically administered TFF2
peptides in rats. Farrell et al. recently developed TFF2-de¢-
cient mice and found that these mice are more susceptible to
indomethacin-induced gastric injury [29]. Konturek et al. re-
ported that repeated administration of aspirin leads to the
upregulation of TFF2 expression and resistance to the aspir-
in-induced gastric mucosal injury in rats [14]. Collectively, the
indomethacin- or aspirin-induced upregulation of TFF2 ex-
pression shown in the present study is likely to be an impor-
tant adaptive mechanism to reduce the extent of NSAIDs-
induced gastric injuries.
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